KOR  ENG
  • IR

  • AbClon’s strong foundations and innovative platforms will help drive the future of
    personalized medicine and safeguard the health and hopes of families.

IR자료

제목 [한양증권] 차별화된 항체신약 플랫폼 보유
첨부파일 20181022_차별화된_항체신약_플랫폼_보유임동락_애널리스트.pdf (1.0M) 날짜 2018-10-22 조회 512

1. 제목 : 차별화된 항체신약 플랫폼 보유

2. 기관명 : 한양증권

3. 작성자 : 임동락 연구원

4. 분량 : 8page

5. 발간일 : 2018.10.22

Designed by CHAIRONE
© AbClon. All rights reserved.